Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child

Paolo Palma, Paola Zangari, Claudia Alteri, Hyppolite K. Tchidjou, Emma C. Manno, Giuseppina Liuzzi, Carlo Federico Perno, Paolo Rossi, Ada Bertoli, Stefania Bernardi

Research output: Contribution to journalArticle

Abstract

Background: HIV genetic diversity implicates major challenges for the control of viral infection by the immune system and for the identification of an effective immunotherapeutic strategy. With the present case report we underline as HIV evolution could be effectively halted by early antiretroviral treatment (eART). Few cases supported this evidence due to the difficulty of performing amplification and sequencing analysis in long-term viral suppressed patients. Here, we reported the case of limited HIV-1 viral evolution over time in a successful early treated child. Case presentation: A perinatally HIV-1 infected infant was treated within 7weeks of age with zidovudine, lamivudine, nevirapine and lopinavir/ritonavir. At antiretroviral treatment (ART) initiation HIV-1 viral load (VL) and CD4 percentage were >500,000 copies/ml and 35%, respectively. Plasma genotypic resistance test showed a wild-type virus. The child reached VL undetectability after 33weeks of combination antiretroviral therapy (cART) since he maintained a stable VL <40copies/ml. After 116weeks on ART we were able to perform amplification and sequencing assay on the plasma virus. At this time VL was <40 copies/ml and CD4 percentage was 40%. Again the genotypic resistance test revealed a wild-type virus. The phylogenetic analysis performed on the HIV-1 pol sequences of the mother and the child revealed that sequences clustered with C subtype reference strains and formed a monophyletic cluster distinct from the other C sequences included in the analysis (bootstrap value >90%). Any major evolutionary divergence was detected. Conclusions: eART limits the viral evolution avoiding the emergence of new viral variants. This result may have important implications in host immune control and may sustain the challenge search of new personalized immunotherapeutic approaches to achieve a prolonged viral remission.

Original languageEnglish
Article number742
JournalBMC Infectious Diseases
Volume16
Issue number1
DOIs
Publication statusPublished - Dec 9 2016

Fingerprint

Viral Load
HIV
HIV-1
Lopinavir
Nevirapine
Ritonavir
Lamivudine
Zidovudine
Virus Diseases
Therapeutics
Immune System
Viruses

Keywords

  • Children
  • Early antiretroviral treatment
  • HIV
  • Immunotherapy
  • Viral evolution

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child. / Palma, Paolo; Zangari, Paola; Alteri, Claudia; Tchidjou, Hyppolite K.; Manno, Emma C.; Liuzzi, Giuseppina; Perno, Carlo Federico; Rossi, Paolo; Bertoli, Ada; Bernardi, Stefania.

In: BMC Infectious Diseases, Vol. 16, No. 1, 742, 09.12.2016.

Research output: Contribution to journalArticle

Palma, Paolo ; Zangari, Paola ; Alteri, Claudia ; Tchidjou, Hyppolite K. ; Manno, Emma C. ; Liuzzi, Giuseppina ; Perno, Carlo Federico ; Rossi, Paolo ; Bertoli, Ada ; Bernardi, Stefania. / Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child. In: BMC Infectious Diseases. 2016 ; Vol. 16, No. 1.
@article{a29fd78c409c4d95b89753b410b3d694,
title = "Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child",
abstract = "Background: HIV genetic diversity implicates major challenges for the control of viral infection by the immune system and for the identification of an effective immunotherapeutic strategy. With the present case report we underline as HIV evolution could be effectively halted by early antiretroviral treatment (eART). Few cases supported this evidence due to the difficulty of performing amplification and sequencing analysis in long-term viral suppressed patients. Here, we reported the case of limited HIV-1 viral evolution over time in a successful early treated child. Case presentation: A perinatally HIV-1 infected infant was treated within 7weeks of age with zidovudine, lamivudine, nevirapine and lopinavir/ritonavir. At antiretroviral treatment (ART) initiation HIV-1 viral load (VL) and CD4 percentage were >500,000 copies/ml and 35{\%}, respectively. Plasma genotypic resistance test showed a wild-type virus. The child reached VL undetectability after 33weeks of combination antiretroviral therapy (cART) since he maintained a stable VL <40copies/ml. After 116weeks on ART we were able to perform amplification and sequencing assay on the plasma virus. At this time VL was <40 copies/ml and CD4 percentage was 40{\%}. Again the genotypic resistance test revealed a wild-type virus. The phylogenetic analysis performed on the HIV-1 pol sequences of the mother and the child revealed that sequences clustered with C subtype reference strains and formed a monophyletic cluster distinct from the other C sequences included in the analysis (bootstrap value >90{\%}). Any major evolutionary divergence was detected. Conclusions: eART limits the viral evolution avoiding the emergence of new viral variants. This result may have important implications in host immune control and may sustain the challenge search of new personalized immunotherapeutic approaches to achieve a prolonged viral remission.",
keywords = "Children, Early antiretroviral treatment, HIV, Immunotherapy, Viral evolution",
author = "Paolo Palma and Paola Zangari and Claudia Alteri and Tchidjou, {Hyppolite K.} and Manno, {Emma C.} and Giuseppina Liuzzi and Perno, {Carlo Federico} and Paolo Rossi and Ada Bertoli and Stefania Bernardi",
year = "2016",
month = "12",
day = "9",
doi = "10.1186/s12879-016-2092-z",
language = "English",
volume = "16",
journal = "BMC Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child

AU - Palma, Paolo

AU - Zangari, Paola

AU - Alteri, Claudia

AU - Tchidjou, Hyppolite K.

AU - Manno, Emma C.

AU - Liuzzi, Giuseppina

AU - Perno, Carlo Federico

AU - Rossi, Paolo

AU - Bertoli, Ada

AU - Bernardi, Stefania

PY - 2016/12/9

Y1 - 2016/12/9

N2 - Background: HIV genetic diversity implicates major challenges for the control of viral infection by the immune system and for the identification of an effective immunotherapeutic strategy. With the present case report we underline as HIV evolution could be effectively halted by early antiretroviral treatment (eART). Few cases supported this evidence due to the difficulty of performing amplification and sequencing analysis in long-term viral suppressed patients. Here, we reported the case of limited HIV-1 viral evolution over time in a successful early treated child. Case presentation: A perinatally HIV-1 infected infant was treated within 7weeks of age with zidovudine, lamivudine, nevirapine and lopinavir/ritonavir. At antiretroviral treatment (ART) initiation HIV-1 viral load (VL) and CD4 percentage were >500,000 copies/ml and 35%, respectively. Plasma genotypic resistance test showed a wild-type virus. The child reached VL undetectability after 33weeks of combination antiretroviral therapy (cART) since he maintained a stable VL <40copies/ml. After 116weeks on ART we were able to perform amplification and sequencing assay on the plasma virus. At this time VL was <40 copies/ml and CD4 percentage was 40%. Again the genotypic resistance test revealed a wild-type virus. The phylogenetic analysis performed on the HIV-1 pol sequences of the mother and the child revealed that sequences clustered with C subtype reference strains and formed a monophyletic cluster distinct from the other C sequences included in the analysis (bootstrap value >90%). Any major evolutionary divergence was detected. Conclusions: eART limits the viral evolution avoiding the emergence of new viral variants. This result may have important implications in host immune control and may sustain the challenge search of new personalized immunotherapeutic approaches to achieve a prolonged viral remission.

AB - Background: HIV genetic diversity implicates major challenges for the control of viral infection by the immune system and for the identification of an effective immunotherapeutic strategy. With the present case report we underline as HIV evolution could be effectively halted by early antiretroviral treatment (eART). Few cases supported this evidence due to the difficulty of performing amplification and sequencing analysis in long-term viral suppressed patients. Here, we reported the case of limited HIV-1 viral evolution over time in a successful early treated child. Case presentation: A perinatally HIV-1 infected infant was treated within 7weeks of age with zidovudine, lamivudine, nevirapine and lopinavir/ritonavir. At antiretroviral treatment (ART) initiation HIV-1 viral load (VL) and CD4 percentage were >500,000 copies/ml and 35%, respectively. Plasma genotypic resistance test showed a wild-type virus. The child reached VL undetectability after 33weeks of combination antiretroviral therapy (cART) since he maintained a stable VL <40copies/ml. After 116weeks on ART we were able to perform amplification and sequencing assay on the plasma virus. At this time VL was <40 copies/ml and CD4 percentage was 40%. Again the genotypic resistance test revealed a wild-type virus. The phylogenetic analysis performed on the HIV-1 pol sequences of the mother and the child revealed that sequences clustered with C subtype reference strains and formed a monophyletic cluster distinct from the other C sequences included in the analysis (bootstrap value >90%). Any major evolutionary divergence was detected. Conclusions: eART limits the viral evolution avoiding the emergence of new viral variants. This result may have important implications in host immune control and may sustain the challenge search of new personalized immunotherapeutic approaches to achieve a prolonged viral remission.

KW - Children

KW - Early antiretroviral treatment

KW - HIV

KW - Immunotherapy

KW - Viral evolution

UR - http://www.scopus.com/inward/record.url?scp=85002625767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002625767&partnerID=8YFLogxK

U2 - 10.1186/s12879-016-2092-z

DO - 10.1186/s12879-016-2092-z

M3 - Article

VL - 16

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

SN - 1471-2334

IS - 1

M1 - 742

ER -